NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $0.75 +0.03 (+3.86%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.75 -0.01 (-0.66%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Palisade Bio Stock (NASDAQ:PALI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Palisade Bio alerts:Sign Up Key Stats Today's Range$0.71▼$0.7550-Day Range$0.61▼$1.2452-Week Range$0.60▼$4.32Volume207,588 shsAverage Volume5.44 million shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalisade Bio has received no research coverage in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Palisade Bio are expected to grow in the coming year, from ($12.43) to ($2.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Palisade Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.05% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 58.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.05% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 58.74%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentPalisade Bio has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.Search Interest9 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows2 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.65% of the stock of Palisade Bio is held by insiders.Percentage Held by InstitutionsOnly 11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PALI Stock News HeadlinesQ3 EPS Estimates for Palisade Bio Reduced by AnalystAugust 17, 2025 | americanbankingnews.comPalisade Bio files to sell 8.9M shares of common stock for holdersAugust 16, 2025 | msn.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 24 at 2:00 AM | InvestorPlace (Ad)Palisade reports outcomes from Phase Ib ulcerative colitis studyAugust 11, 2025 | finance.yahoo.comPalisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative ColitisAugust 8, 2025 | msn.comPalisade Bio Reports Positive Phase 1b Data for PALI-2108 in Ulcerative Colitis Demonstrating Safety and EfficacyAugust 7, 2025 | quiverquant.comQPalisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108August 7, 2025 | globenewswire.comPalisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in ChinaJuly 31, 2025 | globenewswire.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $1.65 on January 1st, 2025. Since then, PALI shares have decreased by 54.3% and is now trading at $0.7540. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) released its earnings results on Monday, August, 11th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.10. When did Palisade Bio's stock split? Palisade Bio shares reverse split on the morning of Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Onconova Therapeutics (ONTX), Sesen Bio (SESN), Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings8/11/2025Today8/24/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Palisade Bio$12.00 High Price Target$16.00 Low Price Target$8.00 Potential Upside/Downside+1,491.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-214.94% Return on Assets-135.09% Debt Debt-to-Equity RatioN/A Current Ratio1.62 Quick Ratio1.62 Sales & Book Value Annual Sales$250 thousand Price / Sales27.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book2.60Miscellaneous Outstanding Shares9,120,000Free Float8,820,000Market Cap$6.88 million OptionableNot Optionable Beta1.35 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:PALI) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.